A Decade of Dysport®: Galderma Celebrates 10 Years Since FDA Approval of Dysport in the U.S.

FORT WORTH, Texas, April 30, 2019 /PRNewswire/ — Galderma Laboratories, L.P., a global leader focused on meeting the world’s increasing skin health needs, proudly celebrates the 10-year FDA approval anniversary of Dysport(abobotulinumtoxinA) for Injection*.

Over the past 10 years, Dysport has established its legacy through various milestones – the brand is approved for clinical use in 72 countries, backed by over 25 years of clinical investigation worldwide in both therapeutic and aesthetic use, and has an established long-term safety profile with a 36-month long-term study. Dysport is fast-acting and long-lasting with natural-looking results to smooth frown lines between the eyebrows. In clinical studies, more than half of users saw improvement in their frown lines in as little as 2-3 days and the results lasting for up to five months.1-4 Dysport also has a high patient satisfaction rate, with 97% of users+ saying they would receive the treatment again and recently, Dysportreceived a 97% “Worth It” rating on RealSelf, making it among the top 10 highest satisfaction ratings for all nonsurgical treatments in 2019.5